Investigational Device Exemption (IDE) Study for the Approval of Closed Loop Stimulation (CLS) and Cardiac Resyncronization Pacing Therapies (CRT) for the Treatment of Atrial Fibrillation (AF) With Ablate and Pace

Atrial Fibrillation Clinical Trial

— AVAIL  

Official title:

AVAIL CLS/CRT: AV-node Ablation With CLS and CRT Pacing Therapies for the Treatment of AF

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00356057
• Other study ID #: G040150
• Status: Terminated
• Phase: N/A
• First received: July 21, 2006
• Last updated: January 29, 2018
• Start date: December 2004
• Est. completion date: June 2008

Study information

• Verified date: January 2018
• Source: Biotronik, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to demonstrate the safety and effectiveness of biventricular pacing over conventional right ventricular pacing in patients with persistent or permanent, symptomatic atrial fibrillation undergoing atrioventricular (AV) node ablation and permanent pacing therapy.

Description:

This study is a multi-center, prospective, randomized, blinded trial. The study will consist of approximately 265 patients who require treatment of persistent or permanent, symptomatic atrial fibrillation by atrioventricular (AV) node ablation and permanent pacing therapy i.e. "Ablate and Pace" therapy. All patients enrolled into the clinical study will be randomly assigned to one of three groups using a randomization ratio of 2:2:1. Patients will be assigned to receive either biventricular (biV) pacing with CLS-based rate adaptive pacing using the legally marketed Protos DR/CLS (Group 1), or biventricular pacing with accelerometer-based rate adaptive pacing using the Stratos LV (Group 2), or right ventricular (RV) pacing with accelerometer-based rate adaptive pacing using the Stratos LV (Group 3). Patients in all three groups will be implanted with legally marketed right and left ventricular pacing leads. The patients, the core lab used to interpret the echocardiographic data and the Clinical Events Committee adjudicating crossover, patient death and congestive heart failure (CHF) hospitalizations will be blinded to the randomization assignment.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 153
• Est. completion date: June 2008
• Est. primary completion date: May 2008
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Meet the indications for therapy

• Persistent, symptomatic AF with poorly controlled rapid ventricular rates or permanent, symptomatic AF with poorly controlled rapid ventricular rates.

• Eligible for AV nodal ablation and permanent pacemaker implantation

• NYHA Class II or III heart failure

• Age = 18 years

• Understand the nature of the procedure

• Ability to tolerate the surgical procedure required for implantation

• Give informed consent

• Able to complete all testing required by the clinical protocol

• Available for follow-up visits on a regular basis at the investigational site

Exclusion Criteria:

• Meet one or more of the contraindications

• Have a life expectancy of less than six months

• Expected to receive heart transplantation within six months

• Enrolled in another cardiovascular or pharmacological clinical investigation

• Patients with an ICD, or being considered for an ICD

• Patients with previously implanted biventricular pacing systems

• Patients with previously implanted single or dual chamber pacing system with > 50% documented ventricular pacing

• Patients with previous AV node ablation

• Six-minute walk test distance greater than 450 meters

• Any condition preventing the patient from being able to perform required testing

• Presence of another life-threatening, underlying illness separate from their cardiac disorder

• Conditions that prohibit placement of any of the lead systems

Related Conditions & MeSH terms

• Atrial Fibrillation
• Congestive Heart Failure
• Heart Failure

Intervention

Device:
• Protos DR/CLS and Stratos LV CRT pacemakers
Protos DR/CLS is a dual chamber pacemaker with CLS rate adaption, Stratos LV is a biventricular pacemaker with accelerometer based rate adaption

Locations

Country	Name	City	State
United States	Lone Star Arrhythmia	Amarillo	Texas
United States	St. Joseph Mercy	Ann Arbor	Michigan
United States	University of Alabama	Birmingham	Alabama
United States	Caritas St. Elizabeth's Medical Center	Boston	Massachusetts
United States	Aultman Hospital	Canton	Ohio
United States	Ohio State University	Columbus	Ohio
United States	Lake Charles Memorial	Lake Charles	Louisiana
United States	McLaren Heart Foundation	Lapeer	Michigan
United States	NYU Medical Center	New York	New York
United States	Spartanburg Regional	Spartanburg	South Carolina

Sponsors (1)

Lead Sponsor	Collaborator
Biotronik, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Average Percentage Improvement From Baseline of the 6-minute Walk Test Distance and Minnesota Living With Heart Failure Quality of Life Score at 6-months	Combined, average percentage improvement in 6-minute walk test distance and Minnessota Living With Heart Failure Quality of Life score from baseline to 6-month follow-up for the Protos DR/CLS (Group 1) and Stratos LV (Group 2) compared with the active control (Group 3). The 6-minute walk test is a test that measure how far a patient can walk in 6 minutes in a standardized walking course. Percent Change (0% (worst)-100% (best))	Change from baseline to six months post-procedure
Primary	Number of Participants Free of System-related Complications (Related to the Device, Leads, or Implant Procedure) at 6 Months Post-procedure	Complication-free rate was evaluated in an equivalence (non-inferiority) format compared to a target of 85% minus delta (10%), where delta is the clinically significant difference for establishing equivalence. This endpoint evaluated system-related complications.	At six months post-procedure
Primary	Number of Participants Free of System-related Complications (Related to the Device, Leads, or Implant Procedure) at 6 Months Post-procedure	Complication-free rate was evaluated in an equivalence (non-inferiority) format compared to a target of 85% minus delta (10%), where delta is the clinically significant difference for establishing equivalence. This endpoint evaluated system-related complications. All Stratos systems (in both the biV and RV pacing arms) were evaluated together as pre-specified in the protocol.	At six months post-procedure
Secondary	Change in Six-minute Walk Test		Change from baseline to 6 months post-procedure
Secondary	Change in Quality Of Life (QOL) Score Over 6 Months Calculated as QOL Score at Baseline - QOL Score at 6 Months	Quality of Life was evaluated using the Minnesota Living with Heart Failure (MLHF) Quality of Life (QOL) Questionnaire.The questionnaire consists of 21 questions to measure the subjects' perception of how their HF and its treatment affected their ability to live as they wanted during the last month. The questions describe different ways in which some people are affected (i.e. physical, socioeconomic, and psychological impairments). If a question does not apply to a subject or is not related to their HF, then they can answer with a 0. If it does apply to them, then they can rate (from 1 to 5) how much it has affected them. From the 21 questions, the lowest possible total score is 0, and the highest possible total score is 105. A lower score is desirable. This outcome was calculated as QOL score at baseline minus QOL score at 6 months. Therefore, a positive change in QOL score represents an improvement in quality of life, while a negative change in QOL score represents a worsening.	Change from baseline to six months post-procedure
Secondary	Cardiac Remodeling Assessments by Echocardiography - Change in Left Ventricular Ejection Fraction		Change from baseline to six months post-procedure
Secondary	Changes in New York Heart Association (NYHA) Classification	The purpose is to evaluate the change in the participant's NYHA classification.; There are four NYHA classes: Class I: Patients with cardiac disease, but without resulting limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea, or anginal pain.; Class II: Patients with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.; Class III: Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes fatigue, palpitation, dyspnea, or anginal pain.; Class IV: Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.	Change from baseline to six months post-procedure
Secondary	Percentage of Patients With Congestive Heart Failure (CHF) Related Hospitalizations		At six months post-procedure
Secondary	Mortality Rate		At six months post-procedure
Secondary	Cardiac Remodeling Assessments by Echocardiography - Change in Left Atrial Volume		Change from baseline to six months post-procedure
Secondary	Cardiac Remodeling Assessments by Echocardiography - Change in Left Ventricular Mass		Change from baseline to six months post-procedure
Secondary	Cardiac Remodeling Assessments by Echocardiography - Change in Left Ventricular End Systolic Volume		Change from baseline to six months post-procedure
Secondary	Cardiac Remodeling Assessments by Echocardiography - Change in Left Ventricular End Diastolic Volume		Change from baseline to six months post-procedure